Better know a biosimilar: extra clinical data key for Boehringer

In an increasingly crowded anti-TNF market, Germany’s Boehringer Ingelheim believes that clinical data is key to differentiating its products and gaining market share.

At rheumatology's main event, the Annual European Congress of Rheumatology (EULAR), the company presented results from its VOLTAIRE study, comparing adalimumab biosimilar candidate BI695501 with Humira in moderately-to-severely active rheumatoid arthritis (RA).

The company’s head of medical affairs for biosimilars, Karsten Kissel, told The Pharma Letter: “It's a very important study, and the results are that the two products are similar in terms of clinical efficacy and safety.”